«Back to Press Releases

January 11, 2006

The Teikoku Group announced today it has licensed the rights to develop and market LAB Pharma’s fast-acting analgesic Fentanyl Taifun in Japan. Under the terms of the agreement, LAB will receive a signing fee, development milestones payments and R&D reimbursements for development activities conducted by Lab in support of the development in Japan. In addition, Teikoku will pay LAB royalties on sales and manufacturing revenues for supplying the finished product. 

Fentanyl Taifun consists of a dry powder formulation of the pain drug Fentanyl, and is delivered by LAB's proprietary Taifun dry powder inhaler. In recently presented clinical results, absorption of Fentanyl after a single inhalation of Fentanyl Taifun was shown to be very rapid, with an average peak concentration reached in one minute. Fentanyl Taifun will be primarily used for the treatment of breakthrough pain in connection with various types of cancer.